GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » A Plus Biotechnology Co Ltd (ROCO:6918) » Definitions » Capex-to-Operating-Cash-Flow

A Plus Biotechnology Co (ROCO:6918) Capex-to-Operating-Cash-Flow : 0.04 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is A Plus Biotechnology Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

A Plus Biotechnology Co's Capital Expenditure for the three months ended in Jun. 2024 was NT$-2.72 Mil. Its Cash Flow from Operations for the three months ended in Jun. 2024 was NT$71.58 Mil.

Hence, A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow for the three months ended in Jun. 2024 was 0.04.


A Plus Biotechnology Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

A Plus Biotechnology Co Capex-to-Operating-Cash-Flow Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
0.13 0.05 4.25 0.61 0.06

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only 1.14 0.29 0.15 0.02 0.04

Competitive Comparison of A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow

For the Medical Devices subindustry, A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow falls into.



A Plus Biotechnology Co Capex-to-Operating-Cash-Flow Calculation

A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-9.805) / 159.104
=0.06

A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-2.723) / 71.581
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


A Plus Biotechnology Co  (ROCO:6918) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


A Plus Biotechnology Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of A Plus Biotechnology Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


A Plus Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants. It engages in the research and development of orthopedic medical products. Aplus locking plate systems feature superior anatomical bone curves and 5-axis CNC manufacturing technology.

A Plus Biotechnology Co Headlines

No Headlines